Financing ·
CAMP4 Therapeutics raises $50.1M in second tranche of private placement following TGA clearance for CMP-002 trial
CAMPCamp4 Therapeutics Corp
CAMP4 Therapeutics closed the second tranche of its private placement on August 3, 2026, generating approximately $50.1 million in gross proceeds. The company issued 10,756,498 shares of common stock at $1.53 per share and 21,925,368 pre-funded warrants at $1.5299 each. Management and directors also purchased an additional 39,306 shares at $1.65 per share. This closing was triggered by regulatory clearance from Australia’s Therapeutic Goods Administration for the Phase 1/2 trial of CMP-002. The total private placement raised approximately $100 million across two closings. CAMP4 Therapeutics is a clinical-stage biopharmaceutical company developing RNA-targeting therapeutics to treat genetic diseases.